Episodes 151-165 of 238
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CEMaximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
CME/CEChairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
CME/CEPatient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
- advertisement
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
- advertisement
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®The Evolving Treatment Landscape for MBC: Emerging Therapies
